Keros Therapeutics (NASDAQ:KROS), a pioneering clinical-stage biopharmaceutical company, today declared the successful closing of the screening process for its TROPOS trial.
This significant milestone marks the advancement of the Phase 2 clinical trial evaluating the efficacy of cibotercept (KER-012) in conjunction with existing treatments in patients suffering from pulmonary arterial hypertension (PAH).
Dr. Jasbir S. Seehra, Chair and CEO of Keros, expressed enthusiasm about the rapid progress, stating, "The closing of screening in the TROPOS trial is a major step forward. The strong interest and swift enrollment we've seen thus far are set to allow us to deliver topline results earlier than initially planned, now targeting the second quarter of 2025."
Cibotercept aims to address disorders related to the dysfunctional signaling within the transforming growth factor-beta (TGF-ß) protein family, which are often linked to severe medical conditions including PAH.
Chris Rovaldi, President and COO of Keros, acknowledged the contributions of the clinical teams and participants involved, stating, "We owe immense gratitude to the TROPOS investigators, research staff, and their patients. Their dedicated involvement is instrumental in propelling us closer to offering a new, differentiated treatment option for those afflicted with PAH."
With the screening phase now closed, Keros anticipates completing patient enrollment by the end of September, setting the stage for presenting the much-anticipated topline data in early 2025.